Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for TransThera Sciences (Nanjing)'s Median PS Value or its related term are showing as below:
HKSE:02617's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.63 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
TransThera Sciences (Nanjing) (HKSE:02617) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
TransThera Sciences (Nanjing)'s Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
10.31
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) Median PS Value Related Terms
TransThera Sciences (Nanjing) Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) Median PS Value Chart
TransThera Sciences (Nanjing) Annual Data
Trend
Dec23
Dec24
Dec25
Median PS Value
0.00
0.00
0.00
TransThera Sciences (Nanjing) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Median PS Value
0.00
0.00
0.00
0.00
0.00
HKSE:02617 vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, TransThera Sciences (Nanjing)'s Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransThera Sciences (Nanjing) Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransThera Sciences (Nanjing)'s Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where TransThera Sciences (Nanjing)'s Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TransThera Sciences (Nanjing)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) (HKSE:02617) has a Median PS Value of HK$0.00 as of Aug. 22, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on TransThera Sciences (Nanjing) and its competitors. According to the industry distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 281 companies in the Biotechnology industry.
Is TransThera Sciences (Nanjing)'s Median PS Value too high?
TransThera Sciences (Nanjing)'s current Median PS Value is HK$0.00. Based on the distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 281 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TransThera Sciences (Nanjing) ranks #999999 out of 281 companies for Median PS Value. This places TransThera Sciences (Nanjing) in the lower half of its industry. The industry median Median PS Value is 0.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on TransThera Sciences (Nanjing) and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransThera Sciences (Nanjing)'s current Median PS Value is HK$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (HKSE:02617) has a current Median PS Value of HK$0.00. The current Median PS Value is HK$0.00. TransThera Sciences (Nanjing)'s overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (HKSE:02617), the current Median PS Value is HK$0.00 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
9GF Score
Get the complete analysis for HKSE:02617
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02617 has been successfully added to your 
